A Study Evaluating the Feasibility and Compliance of Manual Lymphatic Drainage Comparing Indocyanine-Green (ICG) Guided vs. Traditional Guided in Patients Undergoing Axillary Node Dissection for the Treatment of Breast Cancer

Breast cancer is estimated to affect approximately 300,000 women in the US in 2023. Studies demonstrate that 1 in 5 will develop breast cancer related lymphedema secondary to the treatments that they receive. BCRL at this time has no cure, however early detection can prevent the progression to late stage BCRL. At this time a technique of arm massage, manual lymphatic drainage (MLD), is used for treatment. This study investigates a new method of MLD, which is guided by the individual patients' lymphatic anatomy through use of ICG-lymphography.

Trial Details

NCT ID
NCT06327490
Phase
PHASE2
Sponsor
University of Florida
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • ICG-guided manual lymphatic drainage
  • Traditional manual lymphatic drainage
  • Indocyanine green
Locations (sample)
  • Gainesville, Florida, United States|29.65163,-82.32483

Key Eligibility Criteria

  • Adults ≥ 18 years of age
  • Patients undergoing axillary lymph node dissection with or without lymphatic reconstruction at diagnosis
  • Patients must have ICG lymphatic mapping performed prior to axillary lymph node dissection
  • A clinical diagnosis consistent with stage Tis-T4N0-3M0 breast cancer.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →